Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection ... for RSV prevention reach the market. Pfizer is currently leading the race ...

An antibody that can bind to many different types of influenza virus prevented macaques from getting seriously sick, and dying, from a highly pathogenic strain of H5N1 bird flu. The findings could ...

Pfizer is looking to follow ... the crucial first few months of life. AstraZeneca and Sanofi are leading the charge here with nirsevimab, a long-acting antibody designed to provide passive ...

Going forward, AstraZeneca researchers are applying that same approach to different classes of medicines, such as antibodies, which are often used to treat diseases. Antibodies' complexities ...

ADCs are made up of an antibody, a small-molecule payload, and a linker. The new phase of the Pfizer partnership will focus specifically on optimizing payloads. Morris says that PostEra has ...

Merck, aiming for pediatric use, would still join a wider market with the three new vaccines made by Pfizer, GSK and Moderna, as well as earlier monoclonal antibodies like Synagis and Beyfortus.

Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates ... Industry leaders, including Pfizer, F. Hoffmann-La Roche, Astellas Pharma Inc., GSK, and AstraZeneca among others ...

Pfizer: It is one of the largest and most successful ... Lilly’s stock has risen 25% in the past year. AstraZeneca: It boasts a diversified geographical footprint as well as a product portfolio ...

Select listed pharmaceuticals companies including Pfizer Ltd, Novartis India Ltd, AstraZeneca Pharma India Ltd and GSK Pharmaceuticals Ltd shall be the beneficiaries of the budget announcements ...